REZOLUTE, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.66 USD | +2.31% |
|
-22.45% | +168.01% |
| Apr. 18 | JonesTrading Starts Rezolute With Buy Rating, $10 Price Target | MT |
| Mar. 06 | Rezolute, Inc. Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia | CI |
Valuation
| Fiscal Period: June | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 41.66 | 27.28 | 119.2 | 108.5 | 72.92 | 106.7 | - | - |
| Enterprise Value (EV) 1 | 41.66 | 27.28 | 119.2 | 108.5 | 72.92 | 20.74 | 38.74 | 24.74 |
| P/E ratio | -0.54 x | -1.31 x | -5.25 x | -1.43 x | -1.96 x | -2.37 x | -2.48 x | -2.32 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - | 4.54 x | 14.5 x |
| EV / Revenue | - | - | - | - | - | - | 1.65 x | 3.35 x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / FCF | - | - | -5.83 x | - | - | -0.36 x | -0.58 x | -0.3 x |
| FCF Yield | - | - | -17.2% | - | - | -278% | -173% | -334% |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 4,208 | 5,866 | 8,352 | 33,583 | 36,828 | 40,128 | - | - |
| Reference price 2 | 9.900 | 4.650 | 14.27 | 3.230 | 1.980 | 2.660 | 2.660 | 2.660 |
| Announcement Date | 9/10/19 | 10/13/20 | 9/15/21 | 9/15/22 | 9/14/23 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: June | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | 23.49 | 7.385 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -25.94 | - | -22.89 | -41.84 | -55.99 | -65.11 | -60.12 | -89.33 |
| Operating Margin | - | - | - | - | - | - | -255.97% | -1,209.66% |
| Earnings before Tax (EBT) 1 | -30.45 | - | -20.9 | -41.06 | -51.79 | -61.81 | -58.16 | -88.14 |
| Net income 1 | -30.45 | -20.33 | -20.9 | -41.06 | -51.79 | -61.04 | -54.12 | -88.14 |
| Net margin | - | - | - | - | - | - | -230.44% | -1,193.62% |
| EPS 2 | -18.50 | -3.540 | -2.720 | -2.260 | -1.010 | -1.123 | -1.072 | -1.146 |
| Free Cash Flow 1 | - | - | -20.44 | - | - | -57.67 | -66.85 | -82.63 |
| FCF margin | - | - | - | - | - | - | -284.65% | -1,118.95% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 9/10/19 | 10/13/20 | 9/15/21 | 9/15/22 | 9/14/23 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: June | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 | 2025 Q3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -7.64 | -12.15 | -10.75 | -11.3 | -10.22 | -14.39 | -17.14 | -14.24 | -15.91 | -15.19 | -16.4 | -17.4 | -18.04 | -19.2 | -20.41 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -7.836 | -12.59 | -11.21 | -9.423 | -9.831 | -13.56 | -15.67 | -12.73 | -14.52 | -13.91 | -15.9 | -16.37 | -18.04 | -19.2 | -20.41 |
| Net income 1 | -7.836 | -12.59 | -11.21 | -9.423 | -9.831 | -13.56 | -15.67 | -12.73 | -14.52 | -13.91 | -15.9 | -16.37 | -18.04 | -19.2 | -20.41 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -0.9200 | -0.8000 | -0.6500 | -0.3000 | -0.1900 | -0.2600 | -0.3000 | -0.2500 | -0.2800 | -0.2700 | -0.3014 | -0.2814 | -0.3167 | -0.3200 | -0.2900 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/12/21 | 2/9/22 | 5/12/22 | 9/15/22 | 11/9/22 | 2/10/23 | 5/11/23 | 9/14/23 | 11/13/23 | 2/13/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: June | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | - | - | - | - | - | 86 | 68 | 82 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | -20.4 | - | - | -57.7 | -66.9 | -82.6 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 0.05 | - | - | - | 0.15 | - | 0.21 | 0.28 |
| Capex / Sales | - | - | - | - | - | - | 0.89% | 3.73% |
| Announcement Date | 9/10/19 | 10/13/20 | 9/15/21 | 9/15/22 | 9/14/23 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
2.66
USD
Average target price
9.667
USD
Spread / Average Target
+263.41%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +168.01% | 107M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- RZLT Stock
- Financials Rezolute, Inc.
